• March 29 2013 
    Sodium Chloride Injection
    Brass particulates
    Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary nationwide user-level recall of one lot of 0.9% Sodium Chloride Injection, USP, 1000 mL, Flexible Container, NDC 0409-7983-09. This action is due to one confirmed customer report where brass particulate was identified in the primary container in the form of several small grey/brown particles.
    # / Press release: http://www.fda.go...
  • Jan. 26 2013 
    Lactated Ringers and 5% Dextrose Injection, USP
    May contain spore like particulate
    Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary nationwide user-level recall of one lot of Lactated Ringers and 5% Dextrose Injection, USP, 1000 mL, Flexible Container, NDC 0409-7929-09. This action is due to one confirmed customer report where a spore-like structured particulate, consistent with mold, was noted in the solution.
    # / Press release: http://www.fda.go...
  • Dec. 14 2012 
    Carboplatin Injection
    Presence of visible particulates.
    Hospira, Inc. (NYSE: HSP), issued this press release today to further inform the general public about a previously communicated voluntary user-level recall of three lots of Carboplatin Injection due to visible particulates identified during a retain sample inspection. Findings have identified the particles as Carboplatin crystals.
    # / Press release: http://www.fda.go...
  • Oct. 29 2012 
    Infusion Systems
    Potential for interruption of therapy or over/under delivery of medication.
    Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary nationwide Class I recall of Symbiq™ infusion systems (list number 16026 Symbiq™ One-Channel Infuser and list number 16027 Symbiq™ Two-Channel Infuser, all serial numbers). This action is due to infusion pump LCD touch screens that may not respond to user selection, resulting in users possibly experiencing a delayed response and/or the screen registering a different value from the value selected by the user.
    # / Press release: http://www.fda.go...
  • Oct. 5 2012 
    Lactated Ringer’s and 5% Dextrose
    Container Leak and mold contamination
    Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary user-level recall of one lot of Lactated Ringer’s and 5% Dextrose Injection, USP, 1000 mL, Flexible Container, NDC 0409-7929-09. This action is due to one confirmed customer report where a leak was identified in the primary container between the cobra cap and fill-tube seal and a spore-like structured particulate, consistent with mold, was noted in the solution.
    # / Press release: http://www.fda.go...
  • Aug. 15 2012 
    Hydromorphone Injection, USP
    May contain more than the 1 mL labeled fill volume
    Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary user level recall of one lot of Hydromorphone Injection, USP, 2 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1312-30 , due to a reported complaint of a single Carpuject containing more than the 1 mL labeled fill volume.
    # / Press release: http://www.fda.go...
  • Aug. 14 2012 
    Propofol Injectable Emulsion
    Visible particles embedded in the glass
    Hospira, Inc. (NYSE: HSP), the world’s leading provider of injectable drugs and infusion technologies, today announced a nationwide recall of three lots of Propofol Injectable Emulsion, 1%, 1g/100 mL, due to visible particles embedded in the glass to the user level. There may be potential for product to come into contact with the embedded particles and the particles may become dislodged into the solution.
    # / Press release: http://www.fda.go...
  • May 11 2012 
    Hydromorphone Injection, USP
    May contain more than the 1 mL labeled fill volume
    Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary user level recall of one lot of Hydromorphone Injection, USP, 1 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1283-31, due to two reported complaints of a single Carpuject containing more than the 1 mL labeled fill volume. Opioid pain medications such as Hydromorphone have life-threatening consequences if overdosed.
    # / Press release: http://www.fda.go...
  • April 17 2012 
    Morphine Sulfate Injection
    Carpujects syringes contain more than the 1 mL labeled fill volume
    Hospira, Inc. (NYSE: HSP), announced today it is initiating a voluntary user level recall of one lot of Morphine Sulfate Injection USP, 4 mg/mL (C-II), 1 mL fill in 2.5 mL Carpuject, NDC 0409-1258-30, due to a customer report of two Carpujects syringes containing more than the 1 mL labeled fill volume. Opioid pain medications such as morphine have life-threatening consequences if overdosed.
    # / Press release: http://www.fda.go...
  • May 27 2010 
    Propofol Injectable Emulsion 1% and Liposyn™ (Intravenous Fat Emulsion) products which include Liposyn II 10%, Liposyn II 20%, Liposyn III 10%, Liposyn III 20%, and Liposyn III 30%
    may contain particulate matter
    # / Press release: http://www.fda.go...
  •  
    Propofol Injectable Emulsion 1% and Liposyn™ (Intravenous Fat Emulsion) products which include Liposyn II 10%, Liposyn II 20%, Liposyn III 10%, Liposyn III 20%, and Liposyn III 30%
    may contain particulate matter
    # / Press release: http://www.fda.go...
  • Nov. 6 2009 
    Drugs
    May contain particulate matter
    # / Press release: http://www.fda.go...
  •  
    Drugs
    May contain particulate matter
    # / Press release: http://www.fda.go...
  • Aug. 14 2009 
    Medical Device
    Manufacturing problem
    # / Press release: http://www.fda.go...
  •  
    Medical Device
    Manufacturing problem
    # / Press release: http://www.fda.go...